Oncoinvent (ONCIN.OL)

Executive Summary

Oncoinvent is a Norwegian clinical-stage radiopharmaceutical company pioneering Radspherin, a novel alpha-emitting microparticle therapy designed to treat cancers that have metastasized to body cavities, such as peritoneal carcinomatosis from ovarian and colorectal cancers. The proprietary technology uses calcium carbonate microparticles loaded with radium-224 to deliver targeted alpha radiation directly to cancer cells while minimizing damage to healthy tissue. The company is advancing Radspherin through multiple clinical trials: a Phase 2 study (NCT06504147) in ovarian cancer patients with peritoneal carcinomatosis, which started recruiting in mid-2024 and is expected to complete by 2031; a completed Phase 1/2 trial (NCT03732781) in colorectal cancer peritoneal carcinoma; and an active Phase 1 trial (NCT03732768) in ovarian cancer. With a strong scientific rationale and positive early data from earlier trials, Radspherin has the potential to address a significant unmet need in cavity-based metastatic cancers, offering a targeted approach that could improve outcomes while reducing systemic toxicity. Oncoinvent, listed on the Oslo Stock Exchange (ticker: ONCIN.OL), continues to build value around its lead asset, with a valuation of approximately $210 million and a focused pipeline in radiopharmaceuticals.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Interim Data for Radspherin in Ovarian Cancer Peritoneal Carcinomatosis60% success
• Q4 2026Final Results from Phase 1 Trial (NCT03732768) in Ovarian Cancer80% success
• TBDPotential Partnership or Licensing Deal for Radspherin40% success